Please assess the completion status of the following clinical trial:

Trial Title: RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~1. ≥ 18 years old.~2. Patients with metastatic papillary renal cell carcinoma, type I or II.~3. Patients with at least one measurable lesion.~4. Patients with an ECOG Performance Status ≤1.~5. Adequate bone marrow function.~6. Adequate liver function.~7. Adequate renal function.~8. Adequate lipid profile.~Exclusion criteria:~1. Patients who had radiation therapy within 28 days prior to start of study.~2. Patients who have received prior systemic treatment for their metastatic RCC.~3. Patients who received prior therapy with VEGF pathway inhibitor.~4. Patients who have previously received systemic mTOR inhibitors.~5. Patients with a known hypersensitivity everolimus or other rapamycins or to its excipients.~6. Patients with uncontrolled central nervous system (CNS) metastases.~7. Patients receiving chronic systemic treatment with corticosteroids or another immunosuppressive agent.~8. Patients with a known history of HIV seropositivity.~9. Patients with autoimmune hepatitis.~10. Patients with an active, bleeding diathesis.~11. Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study.~12. Patients who have a history of another primary malignancy and off treatment ≤ 3 years, with the exception of non-melanoma skin cancer and carcinoma in situ of the uterine cervix.~13. Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods.~14. Patients who are using other investigational agents or who had received investigational drugs ≤ 4 weeks prior to study treatment start.~15. Patients unwilling to or unable to comply with the protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RAD001 (Type: EXPERIMENTAL): two 5 mg tablets of everolimus orally, once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).